FDA green light for Sarclisa combo in multiple myeloma
CD38 inhibitor approved in combination with carfilzomib and dexamethasone
Read More
Tag: Isatuximab
NICE backs use of new treatment for multiple myeloma
Sanofi’s Sarclisa gets the final green light for use by the NHS with funding from the CDF
Read More
NICE rejects Sanofi’s Sarclisa in preliminary guidelines
It is not certain how much more clinical benefit Sarclisa has over existing therapies, the Institute said
Read More
Sanofi’s Sarclisa cleared in Europe for multiple myeloma
Multiple myeloma is the second most common blood cancer, with around 40,000 new cases per year in Europe
Read More
Sanofi’s Sarclisa cuts death risk in mutiple myeloma
The Phase III IKEMA trial hit its primary endpoint
Read More
CHMP gives Sanofi positive opinion for Sarclisa
Despite available treatments, multiple myeloma remains an incurable malignancy, and is associated with significant patient burden.
Read More
FDA set to review Sanofi’s isatuximab for multiple myeloma
Multiple myeloma is the second most common hematologic malignancy, affecting more than 138,0002 people worldwide.
Read More
Isatuximab shows positive results in Phase III trial for multiple myeloma
A Phase III trial of Sanofi’s isatuximab’s has proven successful, showing that the drug achieved the primary endpoint of prolonging progression free survival in patients with relapsed/refractory multiple myeloma.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
